Study Summary
This study is an open, dose-escalating clinical study, taking patients with relapsed or refractory acute lymphoblastic leukemia as the test subjects, including mouse-derived CAR-T treatment failure or relapse, or for any reason cannot bridge the transplant r/r B-ALL.
Want to learn more about this trial?
Request More InfoInterventions
Senl-h19 CAR-TBIOLOGICAL
Biological: Senl-h19 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Hebei yanda Ludaopei Hospital | Yanda | Hebei | China |